Therapeutic Solutions International, Inc. Stock: price and insider trades · United States
Therapeutic Solutions International, Inc.: what insiders have been doing
Therapeutic Solutions International, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Therapeutic Solutions International, Inc. The previous disclosure was published on 2 October 2024.
Over the whole record (from 2012), the tally stands at no purchases and 6 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
- 10,000,000 shares@ US$0.00092.7% of flowCommon StockSEC:0001493152-24-039151:0
- 55,555,555 shares@ US$0.00096.4% of flowCommon StockSEC:0001493152-24-039152:0
- 13,333,333 shares@ US$0.00061.0% of flowCommon StockSEC:0001493152-24-027797:0
- 10,000,000 shares@ US$0.00061.8% of flowCommon StockSEC:0001493152-24-027081:0
- 20,000,000 shares@ US$0.00061.6% of flowCommon StockSEC:0001493152-24-027079:0
- 25,000,000 shares@ US$0.00082.6% of flowCommon StockSEC:0001493152-24-026652:0
- 10,000,000 shares@ US$0.00082.4% of flowCommon StockSEC:0001493152-24-026656:0
- 10,000,000 shares@ US$0.00082.4% of flowCommon StockSEC:0001493152-24-022093:0
- 37,500,000 shares@ US$0.00083.9% of flowCommon StockSEC:0001493152-24-022090:0
- 42,857,142 shares@ US$0.00074.0% of flowCommon StockSEC:0001493152-24-015329:0
- 15,000,000 shares@ US$0.00073.3% of flowCommon StockSEC:0001493152-24-015326:0
- 10,000,000 shares@ US$0.00092.8% of flowCommon StockSEC:0001493152-24-007810:0
- 10,000,000 shares@ US$0.00091.2% of flowCommon StockSEC:0001493152-24-007808:0
- 20,000,000 shares@ US$0.00159.4% of flowCommon StockSEC:0001493152-23-037416:0
- 70,000,000 shares@ US$0.001514.2% of flowCommon StockSEC:0001493152-23-037414:0
- 4,000,000 shares@ US$0.00496.1% of flowCommon StockSEC:0001493152-23-000989:0
- 4,081,632 shares@ US$0.00492.7% of flowCommon StockSEC:0001493152-23-000987:0
- 4,000,000 shares@ US$0.0067.5% of flowCommon StockSEC:0001493152-22-037188:0
- 4,000,000 shares@ US$0.0063.2% of flowCommon StockSEC:0001493152-22-037187:0
- 3,000,000 shares@ US$0.009910.0% of flowCommon StockSEC:0001493152-22-030365:0
- 3,777,777 shares@ US$0.00995.4% of flowCommon StockSEC:0001493152-22-030360:0
- 1,500,000 shares@ US$0.0112.3% of flowCommon StockSEC:0001493152-22-025506:0
- 2,000,000 shares@ US$0.0116Common StockSEC:0001493152-22-025388:7
- 1,500,000 shares@ US$0.01162.5% of flowCommon StockSEC:0001493152-22-025388:0
- 2,400,000 shares@ US$0.02517.9% of flowCommon StockSEC:0001493152-22-009629:0
25 of 80 declarations
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. (ticker: TSOI) is a U.S.-based micro-cap healthcare company associated with the American over-the-counter market rather than NYSE/NASDAQ at this stage. The company is headquartered in the United States, with SEC filings indicating a corporate move to Elk City, Idaho. In business terms, TSOI positions itself as a biotech and medical-solutions developer focused on immunomodulation, cell-based therapies, and programs linked to oncology and inflammatory diseases. Its SEC disclosures suggest a very small operating base, significant reliance on external financing, and the going-concern and dilution risks that are common among early-stage biopharma names.
From a business-line perspective, the company has historically communicated around several development themes: stem-cell-based therapeutic candidates, immune-system modulation, and clinical or preclinical applications in severe disease settings. One of the most frequently cited assets is JadiCell™, described by the company as a flagship cell-therapy program, alongside additional initiatives tied to cancer and other high-unmet-need indications. TSOI’s competitive position remains highly uncertain and depends on clinical validation, regulatory progress, and its ability to fund research and development over time. In this respect, it is not comparable to large-cap pharmaceutical companies with diversified commercial franchises; instead, its equity story is driven primarily by milestone events and binary outcomes.
Read moreShow less
Geographically, the company appears predominantly U.S.-centric. The SEC filings point to an operational footprint concentrated in Idaho, with historical references to California in earlier corporate documents. There is no clear evidence of a broad international commercial platform comparable to that of a global drug manufacturer. Any broader geographic reach would likely come through potential partnerships, licensing, or future development relationships rather than an established multinational sales network.
Recent highlights seen in SEC filings include insider transactions reported on Form 4, which often attract close attention in this type of stock. The company’s regulatory documents also underscore ongoing liquidity pressure, dependence on future capital raises, and the need to sustain operations while advancing its development pipeline. For French-speaking investors, TSOI should therefore be viewed as a highly speculative U.S. biotech micro-cap, with value anchored more in clinical and financing catalysts than in traditional earnings-based valuation metrics.
